Pathophysiological underpinnings of multiple myeloma progression

Journal of Managed Care Pharmacy

Volumn 14, Issue 7 SUPPL., 2008, Pages

  Jagannath, Sundar ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CALCIUM; CREATININE; HEMOGLOBIN; M PROTEIN; PROTEIN S;

ANEMIA; BLOOD CLOTTING DISORDER; BLOOD VISCOSITY; BONE DESTRUCTION; BONE PAIN; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CANCER STAGING; CHROMOSOME TRANSLOCATION; COMORBIDITY; CYTOGENETICS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FLUID THERAPY; GENE MUTATION; HUMAN; INFECTION; KIDNEY FAILURE; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 54449085400     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.s7-a.7     Document Type: Review

References (18)

1. Multiple Myeloma Research Foundation. Multiple Myeloma: Disease Overview. 2006. Available at: www.multiplemyeloma.org/downloads/ about_myeloma/Disease_Overview.pdf. Accessed August 15, 2008.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-73.
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-87.
4. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301-18.
5. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-20.
6. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-98.
7. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195-202.
8. Joshua D. Pathophysiology - bone disease. Presented at: XIth International Myeloma Workshop; June 5-30, 2007; Kos, Greece. Available at: http://myeloma.org/main.jsp?source=link&source_link_id= 3039&type=article&tab_id=13&menu_id=0&id=2305. Accessed March 14, 2008.
9. Zhan F, Sawyer J, Tricot G. The role of cytogenetics in myeloma. Leukemia. 2006; 20:1484-86.
10. Orlowski RZ. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2006:338-47.
11. Chen L, Li J, Xu W, et al. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol. 2007;29:116-20.
12. Auwerda JJ, Sonneveld P, de Maat M, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica. 2007;92:279-80.
13. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25:5490-505.
14. Lentzsch S, Ehrlich LA, Roodman GD. Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am. 2007;21:1035-49.
15. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008:1-9, epub June 5, 2008.
16. International Myleoma Foundation. Multiple myeloma: renal involvement in multiple myeloma. Available at: http://myeloma.org/ main.jsp?newsletter_type=detail&type= query&tab_id=18menu_id0&id=6&newsletter_id=226. Accessed July 21, 2008.
17. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:717-41.
18. Schwartzberg L. Managed care considerations in the treatment of multiple myeloma. Managed Care Oncol. Spring 2007:14-16, 47.